About Mederi Therapeutics
Mederi Therapeutics is a Healthcare company based in Greenwich (United States) founded in 2008, and was acquired by Restech in April 2018. Minimally invasive RF devices for gastrointestinal diseases are developed. Its focus areas include Life Sciences, Gastroenterology, Medical Devices and Therapeutic Devices. Its legal entity is MEDERI, INC. Its competitors include EndoChoice, EndoGastric Solutions and CoapTech; 3 of its 3 listed competitors have raised funding.
Company details
Mederi Therapeutics develops minimally invasive devices that use radiofrequency energy to treat gastrointestinal system diseases. Solutions developed by the company include Stretta Therapy (trans-oral catheter system uses a proprietary application of RF energy that is low-power and generates low temperatures during a series of 14 one-minute cycles which remodel the lower esophageal sphincter muscle and gastric cardia), and Secca Therapy (trans-anally inserted system uses a proprietary application of RF energy that runs on the dual-purpose RF1 generator). The company has received FDA clearance and CE Mark approval for both its device.
- Headquarters Greenwich, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website mederi-inc.com
- Social LinkedIn X
- Acquired by Restech (Apr 2018)
- Legal Name Mederi, Inc.
Funding Insights of Mederi Therapeutics
- Total Rounds 1
- Last Round Debt – Venture — $18.5M
- First Round $18.5M
(Dec 2013)
- Investors Count 1
All 1 funding rounds of Mederi Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2013 | $18.5M | Debt – Venture | – | – |
2 investors in total: 2 institutional.
Investors in Mederi Therapeutics
Mederi Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Restech and Horizon Technology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
R&D company focused on manufacturing drugs for multiple therapeutic areas | 1992 | horizontechinc.com | Salem, United States | |
Provider of patient health diagnosis and treatment management devices for providers | 2003 | restech.com | Houston, United States |
Investor details for Mederi Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Mederi Therapeutics
3 dated milestones of Mederi Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Mederi Therapeutics is founded.
- Funding First funding round of $18.5M.
- Exit Acquired by Restech.
Competitors of Mederi Therapeutics
Mederi Therapeutics has 3 listed competitors in our database, 3 of them funded. They include EndoChoice, EndoGastric Solutions and CoapTech.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| endochoice.com | 2008 | Alpharetta, United States | $115.96M | 414 | Devices, systems, and services are provided for GI specialists. | |
| endogastricsolutions.com | 2002 | San Mateo, United States | $355.2M | 80 | Incisionless transoral procedures for upper GI diseases are developed. | |
| coaptech.com | 2016 | Baltimore, United States | $16.52M | Minimally invasive gastrostomy feeding tube placement method is developed. |
Detailed competitors of Mederi Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Mederi Therapeutics
Websites that share an audience with Mederi Therapeutics (mederi-inc.com).
Websites whose visitors overlap most with Mederi Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
bananachips.jp | bananachips.jp | 100% | #3,228,360 | – | |
niku-cute.com | niku-cute.com | 90% | #2,268,070 | – |
Top companies in Gastroenterology
3 companies that operate in the same segment as Mederi Therapeutics (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Mederi Therapeutics
Mederi Therapeutics was founded in 2008 and raised its 1st funding round 5 years after it was founded.
Mederi Therapeutics is headquartered in Greenwich, United States. It is registered at Greenwich, Connecticut, United States.
Mederi Therapeutics develops minimally invasive devices that use radiofrequency energy to treat gastrointestinal system diseases. Solutions developed by the company include Stretta Therapy (trans-oral catheter system uses a proprietary application of RF energy that is low-power and generates low temperatures during a series of 14 one-minute cycles which remodel the lower esophageal sphincter muscle and gastric cardia), and Secca Therapy (trans-anally inserted system uses a proprietary application of RF energy that runs on the dual-purpose RF1 generator). The company has received FDA clearance and CE Mark approval for both its device.
Mederi Therapeutics's top competitors include CoapTech, EndoChoice and EndoGastric Solutions.
Mederi Therapeutics has 2 investors. Key investors include Restech, and Horizon Technology.
Mederi Therapeutics operates through Mederi, Inc..
Yes. Mederi Therapeutics was acquired by Restech in April 2018.